Kaya Holdings shifts to psilocybin; tiny sales, $5.8M derivative loss and heavy convertible debt

Kaya Holdings, Inc. (OTCBB: KAYS) - Quick internal snapshot (As of June 30, 2025 / Q2 2025)

What's happening inside the company
Kaya has pivoted from retail cannabis to psychedelic treatment services (The Sacred Mushroom through FDT). Operations show tiny continuing revenues from the new business, significant financing via convertible notes, a large fair-value mark-to-market swing on derivative liabilities, and continued dependence on outside capital. Management is cutting payroll costs (moved from salaried staff to contractors at The Sacred Mushroom) and has a $75,000 license sale funded into escrow but awaiting regulatory approval.

Key facts & figures
- Total assets: $254,430
- Cash and equivalents (ending): $48,146 (up from $39,668)
- Escrow receivable (license sale): $75,000 (included in Other non-current assets)
- Total liabilities: $21,541,194
- Stockholders' deficit (total): $(21,286,764)
- Accumulated deficit: $(42,656,207)
- Working capital deficiency: $12,008,394 (Company disclosure - going concern risk)
- Convertible debt, net of discounts: $8,946,423 (total convertible principal $9,305,222 less discount $358,799)
- Derivative liabilities (fair value): $5,827,706 (up from $2,497,275 at 12/31/24; change = +$3,234,914)
- Accrued interest, current: $3,395,249
- Accounts payable & accrued (total): $647,680; related-party payables $836,050
- Shares outstanding (as of Aug 27, 2025): 41,572,835
- Weighted average shares - basic (six months): 42,664,501

Income statement highlights - factual numbers
Net sales for six months ended June 30, 2025 = $17,149 (three months = $10,097)
$11,705 → Gross profit = $5,444 (three months gross profit = $3,362)
$373,566 (three months = $165,946)
$(368,122) (three months operating loss = $(162,584))
$(401,300) (three months = $(203,819))
$(177,308)
$(3,234,914) - large non-cash loss driving the period results
$(4,113,088) - Basic net loss per share: $(0.10)

Positive aspects (income statement & operational)
- Revenue: the new psilocybin business produced reported net sales ($17,149 YTD) and a positive gross margin ($5,444) - evidence of initial commercial activity.
- Operating expenses fell vs. prior period in several line items (e.g., professional fees and G&A were lower than the six months ended June 30, 2024).
- Cash balance grew to $48,146 from $39,668 (total increase including FX = $8,478) and the company obtained $75,000 in escrow for license sale (potential near-term liquidity if approved).
- Management is taking cost actions (replacing salaried staff with contractors at The Sacred Mushroom) to reduce cash burn.

Negative aspects (income statement & financial health)
- Large consolidated net loss: $(4.11M) for six months - driven primarily by non-cash derivative revaluation of $(3.23M) and ongoing interest/amortization charges.
- Revenue is immaterial relative to liabilities and losses - $17k YTD vs. $21.5M liabilities.
- Derivative liabilities surged to $5.83M (mark-to-market volatility tied to convertible notes and stock price) - a recurring non-cash P&L swing and major source of loss.
- Heavy leverage: convertible debt net ~$8.95M plus current accrued interest $3.40M; many convertible notes include price adjustment provisions (dilution/rachet risk).
- Working capital deficit $12.0M and stockholders' deficit $(21.29M) - company discloses substantial doubt about going concern.
- Taxable payable / accrual: $902,166 (recorded as tax liability); discontinued operations and historic cannabis activity create lingering tax and regulatory exposure.
- Internal control weaknesses and no audit committee - management flagged material weaknesses in controls and procedures (risk to reporting reliability).

Cash flow & liquidity
- Net cash used in operating activities (continuing) for six months: $(390,833); total (including discontinued): $(391,956).
- Net cash provided by financing activities: $395,000 (notes issued).
- Net increase in cash after FX: $8,478 → Ending cash $48,146.
- Company depends on raising capital (equity/debt), alliances, or asset sales - management plan but no guaranteed funding.

Material risks to watch (short list)
- Further derivative revaluations tied to stock volatility and additional convertible issuance (can produce large non-cash losses).
- Dilution risk from numerous convertible notes with price-adjustment features and potential future conversions.
- Going concern: large working capital deficit, heavy debt, and dependence on successful sale/approval of license and further financings.
- Regulatory risk for psilocybin business (state vs federal law) and delays in license transfers (escrowed $75,000 is conditional).
- Internal control weaknesses that may affect timely and accurate financial reporting.

Bottom line - short take
Kaya Holdings (OTCBB: KAYS) has started revenue from its new psilocybin clinic but remains small-scale operationally while carrying outsized financial complexity: heavy convertible debt, large derivative liabilities, significant accrued interest, and a material working-capital shortfall. The headline numbers are a modest gross profit offset by a multi-million-dollar net loss (driven largely by derivative revaluations). The story for investors or counterparties is liquidity-driven: the company needs capital or successful license sales/approvals to stabilize the balance sheet and avoid further dilution or distress. Monitor: derivative liability movements, convertible note activity, escrow/license approval ($75,000), and any successful equity/debt financings or strategic partnerships.